# To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

> **NCT04682587** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 481 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Avelumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04682587
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2021-04-05
- **Final completion:** 2021-04-05
- **Target enrollment:** 481 (ACTUAL)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04682587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04682587, "To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04682587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*